Stimulation of the cortical muscarinic M1 receptor (CHRM1) is proposed as a treatment for schizophrenia, a hypothesis testable using CHRM1 allosteric modulators. Allosteric modulators have been shown to change the activity of CHRMs using cloned human CHRMs and CHRM knockout mice but not human CNS, a prerequisite for them working in humans. Here we show in vitro that BQCA, a positive allosteric CHRM1 modulator, brings about the expected change in affinity of the CHRM1 orthosteric site for acetylcholine in human cortex. Moreover, this effect of BQCA is reduced in the cortex of a subset of subjects with schizophrenia, separated into a discrete population because of a profound loss of cortical . These data suggest the orthosteric and allosteric sites on CHRMs respond differently to divalent cations and the effects of allosteric modulation of the cortical CHRM1 is reduced in a subset of people with schizophrenia, a finding that may have ramifications for the use of CHRM1 allosteric modulators in the treatment of schizophrenia.
INTRODUCTION
Post-mortem CNS studies and a neuroimaging study (see Raedler et al, 2007) have reported lower levels of cortical muscarinic receptors (CHRMs) in people with schizophrenia due, at least in part, to lower levels of CHRM1 (Dean et al, 2002; Mancama et al, 2003; Scarr et al, 2006) . The recognition that schizophrenia is a syndrome (Schwarz et al, 2013 ) is relevant to these findings because it has been shown that lower levels of cortical CHRM1 are restricted to a subgroup of people with schizophrenia ) (muscarinic receptor-deficit schizophrenia (MRDS)) who may have a different etiology that includes altered agonist-induced CHRM1-mediated G-protein recruitment (Salah-Uddin et al, 2009) , differentiating CHRM1 promoter methylation (Scarr et al, 2013) , and increased levels of a CHRM1 targeting microRNA (Scarr et al, 2013) .
Based on data from human and preclinical pharmacological studies, it was suggested that stimulating cortical CHRM1 would alleviate some symptoms of schizophrenia . This hypothesis gained support from the finding that, compared with placebo, xanomeline, a CHRM1/CHRM4 agonist, reduced the severity of positive, negative, and cognitive deficit symptoms in treatmentresistant schizophrenia (Shekhar et al, 2008) . Unfortunately, despite this finding, the severe peripheral side effects of xanomeline (Bodick et al, 1997) , its complex pharmacology (Shannon et al, 1994) and metabolic instability, as well as a high hepatic first-pass effect (Mirza et al, 2003) prevented further clinical development. Notably, preclinical findings suggests xanomeline's effects on cognition, attention, and learning were mediated through CHRM1 (Bymaster et al, 2003) and the antipsychotic effects were mediated by CHRM4 modulating dopamine levels (Woolley et al, 2009) .
Structural homology at the orthosteric binding site across CHRMs (Wess et al, 2007) has thus far thwarted attempts to synthesize compounds specific to individual CHRMs. However, the discovery of allosteric binding sites specific to each CHRM (Lazareno and Birdsall, 1995) now offers an opportunity to independently modulate the activity of each of these five receptors. For example, using cloned human receptors, behavioral studies in wild-type and Chrm −/− mice, pharmacology at the rat Chrm1, and effects on rat behavior strongly suggests that the positive allosteric modulator [1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid] (BQCA) is highly selective, if not specific, for the CHRM1 (Ma et al, 2009; Shirey et al, 2009) . Notably, a reliable method is now available for quantifying the effect of BQCA at the CHRM1 that involves measuring the ability of the drug to decrease the concentration of acetylcholine required to displace [ (Ma et al, 2009; Shirey et al, 2009) .
We have previously shown that the pharmacology of a compound established using models such as human cloned receptors does not necessarily correspond with the pharmacology of the drug in human CNS tissue . Therefore, because of our interest in CHRM1 as a drug target, we wanted to show the defining pharmacological response to BQCA established using cloned receptors was detectable using human cortex. In addition, our interest in CHRM1 in schizophrenia led us to determine whether the action of BQCA on [ 3 H]NMS binding might be altered using cortical membranes from subjects with the disorder, particularly in subjects with MRDS compared with non-MRDS ). In addition, as [ 3 H]NMS binding has been reported to be higher in the cortex of people with schizophrenia (Watanabe et al, 1983) we measured the binding parameters for that radioligand to cortical membranes from subjects with the disorder. Finally, to allow us to better understand the potential impact of differing methods used for [ ]pirenzepine binding, we investigated whether the binding of these radioligands was ion dependent. Our studies were completed using Brodmann's area (BA) 6 because we confirmed that the marked decrease in [ 3 H]pirenzepine binding in subjects with MRDS, which was first identified in BA 9, was detectable in BA 6 (Seo et al, 2014) and because we had shown that this region of the cortex had decreased levels of neuregulin 1 (NRG1) (Barakat et al, 2010) . As changes in NRG1 gene sequence has been associated with an increased risk of schizophrenia (Stefansson et al, 2002) , we postulated molecular changes in BA 6 may reflect the impact of a biology dictated by an increased genetic predisposition for the disorder.
MATERIALS AND METHODS

Tissue Collection, Diagnostic Validation, and Membrane Preparation
After approval from the Ethics Committee of the Victorian Institute of Forensic Medicine, tissue was collected postmortem and diagnostic evaluation completed on a series of subjects with a likely history of psychiatric illness and age/sex-matched subjects who appeared to have no history of a psychiatric disorder as described previously (Supplementary Methods) . The left cerebral hemisphere was sliced according to a standardized protocol and then rapidly frozen to − 80°C for storage until required (Dean et al, 1999) .
Following approval from the Tissue Access Committee of the Victorian Brain Bank Network, tissue was obtained from BA 6 (a cortical region that includes the anterior part of the paracentral lobule and the adjacent superior gyrus, the dorsal bank of the callosomarginal sulcus (minus its posterior third), and the bases of superior and middle frontal gyrus and pre-central gyrus not included in BA 4 (Garey, 1994) ) from five subjects for methodological optimization. In addition, tissue was obtained from BA 6 from 40 subjects with schizophrenia and 20 age/sex-matched controls (demographics summarized in Table 1 (Seo et al, 2014) . The subjects with schizophrenia comprised 20 MRDS and 20 non-MRDS cases; the 20 subjects with MRDS were selected from the cases that we have previously shown separated into a subgroup within the syndrome of schizophrenia because of a marked loss of [ 
Membrane Preparations for [ 3 H]NMS Binding
Membranes were prepared using methodologies similar to that used for human cloned CHRMs (Shirey et al, 2009) . Human cortices were thawed on ice and homogenized into H]NMS (0.01 to 2 nM: triplicate) to washed human cortical membranes (n = 3; 0.1 mg protein) was measured in the absence (total binding (TB)) and presence (nonspecific binding (NSB)) of 1 mM acetylcholine, and this and all subsequent experiments were completed in a final vol of 1 ml made up with Assay Buffer. After incubating for 2 h at room temperature (RT), 5 ml of ice cold Assay Buffer was added to each tube and the bound radioactivity filtered onto a Whatman GF/B filter. Each filter was washed thrice with ice-cold 0.9% saline and placed into 5 ml of UltimateGold scintillation cocktail. After 1 h, the radioactivity on each filter paper was counted using a Tri-Carb 2910 TR (PerkinElmer) and corrected for radioactive decay and counting efficiency before being converted from counts per min to specific binding of fmol/mg protein; TB and NSB at each concentration of [ From these experiments, two binding parameters could be measured that were the change in ΔlogEC50 for the displacement of [ 3 H]NMS by acetylcholine at different concentrations of BQCA and the area encompassed between the acetylcholine displaceable [
Statistical Analysis
Because of difficulties in determining data distribution on small sample sizes (D'Agostino et al, 1990), all statistical analyses were completed using parametric analyses and effect size determined using Cohen's d values (Cohen, 1988) . Again, because of small sample sizes, only linear regression analyses with r 2 40.49 were taken as reflecting strong enough relationships between two variables to warrant acceptance as potential covariates (Cook and Weisberg, 1999) and in such cases an ANCOVA was used to determine the impact of such factors on our analyses. Donor demographic, drug, and CNS collection data were assessed using GraphPad Prism and either one-way ANOVA followed by post hoc Tukey's multiple comparison test (Motulsky, 1999) comparing data across cohorts or Student t-tests (if 2 cohorts). The sex ratios and rates of suicide in the different cohorts were compared using Fisher's exact test. Variation in experimental data was assessed using Student's t-tests or one-way ANOVA followed by post hoc Dunnett's comparison with control. Relationships between experimental variables and demographic, tissue collection, and pharmacological data were assessed using linear regression. If strong relationships were revealed, and there was no variation in the nonexperimental data with group (Miller and Chapman, 2001) , the variation in the experimental data was reassessed using the ANCOVA with the appropriate nonexperimental data as covariant(s) using Minitab 15. Data are presented as mean ± SEM unless otherwise stated. 
RESULTS AND DISCUSSION
Where we describe results on subjects with schizophrenia, these data related to the combined MRDS and non-MRDS data. 
Studies on Schizophrenia
There were no significant differences in sex ratio, age, PMI, or CNS pH between the subjects with schizophrenia and the age/sex-matched controls (Table 1 and Supplementary  Table 1 ). The frequency of suicide completion was significantly higher in subjects with schizophrenia. There were no significant differences in sex ratio, age, PMI, or CNS pH between MRDS, non-MRDS, and controls. There were no differences in FRADD, LEAP, FRBD, or FRAcD between MRDS and controls. The frequency of suicide completion was higher in non-MRDS compared with MRDS. The frequency of antipsychotic (p = 0.18), benzodiazepine (p = 0.74), or anticholinergic (p = 0.52) drug prescription at death did not vary between MRDS and non-MRDS.
Compared with controls, the affinity (Kd; nM: schizophrenia = 0.26 ± 0.02 vs Controls = 0.13 ± 0.007; Cohen's d = 0.87; Figure 2a The Area BQCA Curve was not different in schizophrenia compared with controls (p = 0.16; Figure 3) . However, the Area BQCA Curve was lower in subjects with MRDS (1460 ± 225 Arbitrary (Arb) Units) compared with non-MRDS (2710 ± 236 Arb Units) and controls (2572 ± 295 Arb Units; po0.01; Cohen's d = − 0.948).
The only strong relationship ascertained was between the affinity for [ Table 2 ); there is no clear explanation why there was such a relationship, especially given the absence of correlation between the maximal number of binding sites measured using the same radioligands.
There were no strong or significant correlations between any experimental measure and age, PMI, CNS pH, DI, FRADD, LEAP, or FRBD (Supplementary Table 3A) . Neither the affinity (p = 0.82; p = 0.11) nor density (p = 0.13, p = 0.19) of [ Table 3B ). These data show that the different rates of suicide completion in MRDS versus non-MRDS was not a significant confound for this study. There were no significant differences in the affinity (p = 0.92) or density (p = 0.07) of [ 3 H]NMS binding or Area BQCA Curves (p = 0.56) in subjects with schizophrenia whether or not they were being prescribed anticholinergic agents close to death.
The lack of change in density of [ 3 H]NMS binding was significant because the selection of subjects with schizophrenia for this study was dictated by their levels of cortical 
Ion Dependency of Radioligand Binding
We postulated the different outcomes from using [ . BQCA has been shown to be highly selective for the allosteric site on the CHRM1 (Ma et al, 2009) , one of the five CHRMs in human CNS . Therefore, the ability of BQCA to modulate the effects of acetylcholine on [ 3 H]NMS binding to cortical membranes is likely mediated by CHRM1. Moreover, we have shown the Area BQCA Curves BQCA modulation of cortical [ strongly correlates with the amount of cortical membrane available for radioligand binding, suggesting this measure would appear to be a novel and specific measure of cortical CHRM1 levels.
In addition to measuring the effects of BQCA Curves we showed that there was no change in the density of [ 3 H]NMS binding in the cortex of subjects with schizophrenia. These data agree with a study using another pan-muscarinic receptor antagonist, [ 3 H]QNB, that reported no change in muscarinic receptor density in medial frontal cortex from subjects with schizophrenia (Watanabe et al, 1983) ; this study did report increased radioligand binding in the orbitofrontal cortex from subjects with the disorder. Our data on [ argue that carefully constructed drug trials using CHRM1 imaging, to identify subjects with low CHRM1, may be required to ensure the benefits of CHRM1 allosteric modulation in schizophrenia are not masked because of the inclusion of subjects with low cortical CHRM1. 
FUNDING AND DISCLOSURE
